Naproxen/pregabalin- Xgene Pharmaceutical

Drug Profile

Naproxen/pregabalin- Xgene Pharmaceutical

Alternative Names: Naproxen/pregabalin; Pregabalin/naproxen; XG005

Latest Information Update: 14 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Xgene Pharmaceutical
  • Class Aminobutyric acids; Analgesics; Antiepileptic drugs; Antipyretics; Antirheumatics; Anxiolytics; Naphthaleneacetic acids; Neuroprotectants; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action CACNA2D1 protein modulators; Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Pain

Most Recent Events

  • 18 Jan 2018 Xgene Pharmaceutical completes a phase I trial in Pain in Australia (ACTRN12617001330336)
  • 12 Oct 2017 Chemical structure information added
  • 03 Oct 2017 Phase-I clinical trials in Pain (In volunteers) in Australia (PO) (ACTRN12617001330336p)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top